306 related articles for article (PubMed ID: 9892228)
1. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
Bruttomesso D; Pianta A; Mari A; Valerio A; Marescotti MC; Avogaro A; Tiengo A; Del Prato S
Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
[TBL] [Abstract][Full Text] [Related]
2. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
3. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.
Koivisto VA; Tuominen JA; Ebeling P
Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929
[TBL] [Abstract][Full Text] [Related]
4. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
[TBL] [Abstract][Full Text] [Related]
5. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM.
Torlone E; Pampanelli S; Lalli C; Del Sindaco P; Di Vincenzo A; Rambotti AM; Modarelli F; Epifano L; Kassi G; Perriello G; Brunetti P; Bolli G
Diabetes Care; 1996 Sep; 19(9):945-52. PubMed ID: 8875087
[TBL] [Abstract][Full Text] [Related]
6. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
Attia N; Jones TW; Holcombe J; Tamborlane WV
Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
[TBL] [Abstract][Full Text] [Related]
7. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
[TBL] [Abstract][Full Text] [Related]
8. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
Rave K; Heise T; Pfützner A; Heinemann L; Sawicki PT
Diabetes Care; 2001 May; 24(5):886-90. PubMed ID: 11347749
[TBL] [Abstract][Full Text] [Related]
9. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes.
Hedman CA; Orre-Pettersson AC; Lindström T; Arnqvist HJ
Clin Endocrinol (Oxf); 2001 Jul; 55(1):107-12. PubMed ID: 11453959
[TBL] [Abstract][Full Text] [Related]
10. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
Burge MR; Waters DL; Holcombe JH; Schade DS
J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
[TBL] [Abstract][Full Text] [Related]
12. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy.
Ruggenenti P; Flores C; Aros C; Ene-Iordache B; Trevisan R; Ottomano C; Remuzzi G
Diabetes Care; 2003 Feb; 26(2):502-9. PubMed ID: 12547889
[TBL] [Abstract][Full Text] [Related]
13. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
14. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
15. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes.
Murase Y; Yagi K; Sugihara M; Chujo D; Otsuji M; Muramoto H; Mabuchi H
Intern Med; 2004 Sep; 43(9):779-86. PubMed ID: 15497510
[TBL] [Abstract][Full Text] [Related]
16. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
17. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
Rassam AG; Zeise TM; Burge MR; Schade DS
Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
[TBL] [Abstract][Full Text] [Related]
18. Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus.
Paquot N; Roulin D; Schneiter P; Ruiz J; Lefebvre P; Pahud P; Tappy L
Diabetes Metab; 1998 Dec; 24(6):523-8. PubMed ID: 9932219
[TBL] [Abstract][Full Text] [Related]
19. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
20. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
Basu R; Basu A; Nielsen M; Shah P; Rizza RA
J Clin Endocrinol Metab; 1999 Jul; 84(7):2314-9. PubMed ID: 10404795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
